Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints

Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.